CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
甘草酸治疗 CAR-T 细胞疗法所致 CRS 的药理学视角
英文原题：Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective.
查看英文原题
Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T（CAR-T）细胞疗法有望彻底改变血液系统恶性肿瘤乃至其他肿瘤的管理。然而，其主要副作用细胞因子释放综合征（CRS）仍是临床应用的重大挑战。目前临床指南建议使用tocilizumab（TCZ）和糖皮质激素治疗CAR-T 细胞疗法所致CRS。但这两种药物的理论风险可能降低临床医生使用它们的意愿，最佳治疗仍有争议。CAR-T 治疗诱发CRS的管理是当前研究重点。甘草酸具有多种药理作用、耐受性良好且价格低廉，是CRS一种理想的替代治疗选择，也可弥补TCZ和糖皮质激素的不足。本文从药理作用角度简要讨论甘草酸治疗CAR-T 细胞疗法所致CRS的潜在价值。
展开英文摘要原文
Chimeric antigen receptor T (CAR T)-cell therapy promises to revolutionize the management of hematologic malignancies and possibly other tumors.
However, the main side effect of cytokine release syndrome (CRS) is a great challenge for its clinical application. Currently, treatment of CRS caused by CAR T-cell therapy is limited to tocilizumab (TCZ) and corticosteroids in clinical guidelines.
However, the theoretical risks of these two agents may curb clinicians' enthusiasm for their application, and the optimal treatment is still debated. CAR T-cell therapy induced-CRS treatment is a current research focus. Glycyrrhizin, which has diverse pharmacological effects, good tolerance, and affordability, is an ideal therapeutic alternative for CRS.
It can also overcome the shortcoming of TCZ and corticosteroids. In this brief article, we discuss the therapeutic potential of glycyrrhizin for treating CRS caused by CAR T-cell therapy from the perspective of its pharmacological action.
论文信息
- 作者
- Qi X、Li J、Luo P
- 单位
- Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.China
- 期刊
- Frontiers in pharmacology2023
- 原文标识
- PubMed 36923358 · DOI 10.3389/fphar.2023.1134174
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →